Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Residual breast tissue after mastectomy and reconstruction: A substudy of the Spatial location of breast cancer local rECurRence aftEr masTectomy (SECRET) project.
Kaidar-Person O, Sklair-Levy M, Anaby D, Bernstein-Molho R, van Maaren MC, de Munck L, de Ruysscher D, Offersen B, Poortmans P, Boersma LJ; SECRET group. Kaidar-Person O, et al. Among authors: de munck l. Eur J Surg Oncol. 2024 Nov;50(11):108607. doi: 10.1016/j.ejso.2024.108607. Epub 2024 Aug 16. Eur J Surg Oncol. 2024. PMID: 39191132
10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study.
van Maaren MC, de Munck L, de Bock GH, Jobsen JJ, van Dalen T, Linn SC, Poortmans P, Strobbe LJA, Siesling S. van Maaren MC, et al. Among authors: de munck l, de bock gh. Lancet Oncol. 2016 Aug;17(8):1158-1170. doi: 10.1016/S1470-2045(16)30067-5. Epub 2016 Jun 22. Lancet Oncol. 2016. PMID: 27344114
Breast-conserving therapy versus mastectomy in T1-2N2 stage breast cancer: a population-based study on 10-year overall, relative, and distant metastasis-free survival in 3071 patients.
van Maaren MC, de Munck L, Jobsen JJ, Poortmans P, de Bock GH, Siesling S, Strobbe LJA. van Maaren MC, et al. Among authors: de munck l, de bock gh. Breast Cancer Res Treat. 2016 Dec;160(3):511-521. doi: 10.1007/s10549-016-4012-8. Epub 2016 Oct 11. Breast Cancer Res Treat. 2016. PMID: 27730424
Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients.
Goorts B, van Nijnatten TJ, de Munck L, Moossdorff M, Heuts EM, de Boer M, Lobbes MB, Smidt ML. Goorts B, et al. Among authors: de boer m, de munck l. Breast Cancer Res Treat. 2017 May;163(1):83-91. doi: 10.1007/s10549-017-4155-2. Epub 2017 Feb 15. Breast Cancer Res Treat. 2017. PMID: 28205044 Free PMC article.
Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases.
van Nijnatten TJ, Simons JM, Moossdorff M, de Munck L, Lobbes MB, van der Pol CC, Koppert LB, Luiten EJ, Smidt ML. van Nijnatten TJ, et al. Among authors: de munck l. Breast Cancer Res Treat. 2017 May;163(1):159-166. doi: 10.1007/s10549-017-4157-0. Epub 2017 Feb 17. Breast Cancer Res Treat. 2017. PMID: 28213782 Free PMC article.
TNM classification and the need for revision of pN3a breast cancer.
van Nijnatten TJA, Moossdorff M, de Munck L, Goorts B, Vane MLG, Keymeulen KBMI, Beets-Tan RGH, Lobbes MBI, Smidt ML. van Nijnatten TJA, et al. Among authors: de munck l. Eur J Cancer. 2017 Jul;79:23-30. doi: 10.1016/j.ejca.2017.04.002. Eur J Cancer. 2017. PMID: 28458119
80 results